Liu Jian, Xu Jie-Hui, Xu Wen, Liang Guan-Lu, Lou Ji-Xian, Wang Yi, Wen Ji-Quan, Cao Yong-Bao
Department of Ophthalmology, Zhejiang Hospital, Hangzhou 310012, Zhejiang Province, China.
Eye Center, the Second Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou 310009, Zhejiang Province, China.
Int J Ophthalmol. 2017 Jul 18;10(7):1126-1133. doi: 10.18240/ijo.2017.07.17. eCollection 2017.
To evaluate the clinical effect of bevacizumab in pterygium treatment.
A systematic review and quantitative Meta-analysis was performed. PubMed, EMBASE, Web of Science and Cochrane database were searched for eligible literatures published in English until June 2016. The endpoint was recurrence rate and pooled risk ratio (RR) was calculated.
Nine eligible studies were included and Meta-analysis results showed no significantly difference in patients treated with bevacizumab in short term follow-up [3mo: RR=0.70 (0.34, 1.45); 6mo: RR=0.55 (0.23, 1.32)] compared with control groups. No significant effects were observed in favor of bevacizumab in subgroup analyses: patients with subconjunctival injection of bevacizumab [3mo: RR=0.95 (0.70, 1.29); 6mo: RR=0.83 (0.55, 1.28)], primary pterygium [3mo: RR=0.59 (0.23, 1.54; 6mo: RR=0.59 (0.23, 1.53)], simple pterygium excision [3mo: 0.32 (0.05, 2.04), =0.23; 6mo: 0.27 (0.05, 1.53)] and excision with conjunctival autograft [3mo: 1.51 (0.25, 9.15); 6mo: 1.11 (0.06, 21.69)].
In this Meta-analysis, we did not found the significant effect of bevacizumab in pterygium treatment, at least in short term follow-up (3mo and 6mo).
评估贝伐单抗在翼状胬肉治疗中的临床效果。
进行系统评价和定量Meta分析。检索PubMed、EMBASE、Web of Science和Cochrane数据库，查找截至2016年6月发表的符合条件的英文文献。终点指标为复发率，并计算合并风险比（RR）。
纳入9项符合条件的研究，Meta分析结果显示，与对照组相比，短期随访（3个月：RR = 0.70（0.34，1.45）；6个月：RR = 0.55（0.23，1.32））时接受贝伐单抗治疗的患者无显著差异。在亚组分析中未观察到贝伐单抗有显著效果：结膜下注射贝伐单抗的患者（3个月：RR = 0.95（0.70，1.29）；6个月：RR = 0.83（0.55，1.28））、原发性翼状胬肉（3个月：RR = 0.59（0.23，1.54）；6个月：RR = 0.59（0.23，1.53））、单纯翼状胬肉切除术（3个月：0.32（0.05，2.04），RR = 0.23；6个月：0.27（0.05，1.53））以及联合结膜自体移植切除术（3个月：1.51（0.25，9.15）；6个月：1.11（0.06，21.69））。
在这项Meta分析中，我们未发现贝伐单抗在翼状胬肉治疗中有显著效果，至少在短期随访（3个月和6个月）中如此。
